NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials

BACKGROUND: Nonalcoholic Fatty Liver Disease (NAFLD) has become a significant public health concern, affecting approximately one-fourth of the population. Despite its prevalence, no FDA-approved drug treatments specifically target NAFLD. AIM: To provide a review of clinical trials investigating the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hegazi, Omar E., Alalalmeh, Samer O., Alnuaimi, Ghala Rashid Humaid, Shahwan, Moyad, Jairoun, Ammar Abdulrahman, Alorfi, Nasser M., Majrashi, Shaker A., Alkhanani, Mustfa Faisal, Alkhattabi, Abdullah, Alourfi, Mansour M., Alsolami, Faris A., Alsharif, Saeed, Alshahrani, Hatim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433184/
https://www.ncbi.nlm.nih.gov/pubmed/37601777
http://dx.doi.org/10.3389/fmed.2023.1227046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433184/
https://www.ncbi.nlm.nih.gov/pubmed/37601777
http://dx.doi.org/10.3389/fmed.2023.1227046

Ejemplares similares